United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $530.42, for a total transaction of $5,038,990.00. Following the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $172,091,056.06. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
United Therapeutics Stock Performance
Shares of UTHR stock opened at $523.63 on Wednesday. The firm's 50 day moving average price is $546.23 and its 200-day moving average price is $532.01. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm has a market cap of $22.23 billion, a P/E ratio of 19.33, a P/E/G ratio of 1.77 and a beta of 0.58.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the business posted $6.63 EPS. The firm's revenue for the quarter was down 1.6% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
UTHR has been the topic of several research analyst reports. TD Cowen reiterated a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. JPMorgan Chase & Co. lifted their target price on United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research report on Thursday, July 23rd. Weiss Ratings reiterated a "buy (b)" rating on shares of United Therapeutics in a research note on Thursday, June 11th. Finally, HC Wainwright increased their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research report on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $648.33.
Check Out Our Latest Stock Report on UTHR
Institutional Trading of United Therapeutics
A number of large investors have recently modified their holdings of UTHR. Handelsbanken Fonder AB boosted its holdings in United Therapeutics by 4.1% in the second quarter. Handelsbanken Fonder AB now owns 13,120 shares of the biotechnology company's stock valued at $7,109,000 after purchasing an additional 520 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab increased its holdings in United Therapeutics by 7.4% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 11,058 shares of the biotechnology company's stock worth $5,992,000 after purchasing an additional 760 shares during the period. Assenagon Asset Management S.A. increased its holdings in United Therapeutics by 79.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 84,538 shares of the biotechnology company's stock worth $45,805,000 after purchasing an additional 37,355 shares during the period. GAMMA Investing LLC raised its position in United Therapeutics by 10.3% in the 2nd quarter. GAMMA Investing LLC now owns 1,769 shares of the biotechnology company's stock valued at $958,000 after purchasing an additional 165 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in United Therapeutics by 93.6% in the 2nd quarter. Versant Capital Management Inc now owns 182 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 88 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
